PepDDG V4, original Figure 1. Author-authorized excerpt.
Open original paper figure ↗ · Source ↗ · Author-authorized figure excerpt
PepDDG ↗
How do mutations change peptide binding?
RESEARCHER · BUILDER · CURIOUS HUMAN
Serious science.
Playful minds.
Peptide possibilities.
I’m Richard. I work at the intersection of peptides and AI, and build a harness for research agents to learn from experience, examine their reasoning, and evolve.
LIFE / BEYOND SCIENCE
Beyond science, there is a world.
RESEARCH / QUESTIONS INTO METHODS
Questions, turned into methods.
Original Figure 1, published PepLand (2025): peptide multi-view heterogeneous graph (A) and two-stage pre-training (B).
Open original paper figure ↗ · Source ↗ · CC BY 4.0
PepLand ↗
Learning representations from peptide structure.
Zhang et al., PepHarmony, arXiv v1 (2024), Figure 1. Complete original, unchanged.
Open original paper figure ↗ · Source ↗ · CC BY-NC-ND 4.0
PepHarmony ↗
Connecting peptide sequences and structures.
DIGITAL TWIN LAB / UNDER CONSTRUCTION
Give research a memory.
A research harness for methods, experience and judgment, with a knowledge Wiki connecting evidence. Improving peptide design, and the system producing it.
TWO PROJECTS / REAL DEVELOPMENT FOOTPRINTS
See the work, day by day.
Two date-aligned tracks record actual commits. Development activity and scientific capability are measured separately.
agentic_ai_platform
Actual commits across 30 days
Independent scale: 0 → 272 commits/day; color intensity cannot be compared across tracks.
knowledge_wiki
Actual commits across 30 days
Independent scale: 0 → 2 commits/day; color intensity cannot be compared across tracks.
UTC Partial day
agentic_ai_platform21commits
knowledge_wiki0commits
—: outside coverage / unavailable; 0: observed with no commits. Today is a partial day. Select any cell by pointer or keyboard.
Source observed at: · UTC
Non-merge commits are counted from the full history of the server default-main snapshot, using committer time. PR data is not connected; missing values are not counted as zero.
CAPABILITIES / PUBLIC EVIDENCE
Progress, with evidence to inspect.
Up to three recent public records: what changed, its validation and the next step. Development activity and capability gains are kept distinct.
Record scope
2026-10-08 · UTC · 2026-10-09T20:15:32.723537+00:00
RESEARCH / A DATED SNAPSHOT
A little more, over time.
Citations are one view of how research travels. Whether a method works still comes back to data, controls, and reproducible evidence.
About me ↗RECENT NOTES
Around research & work.
- Company news
Syneron Bio Announces Completion of $150 Million Series B Financing. ↗
Syneron Bio announced a $150 million Series B financing to advance its Synova macrocyclic peptide discovery platform and support its pipeline’s progression toward clinical development.
- Company news
Syneron Bio Closes Nearly $100M in Series A and A+ Rounds. ↗
Syneron Bio announced nearly $100 million across its Series A and A+ financing rounds. This is a company financing announcement.
- Company news
Syneron Bio Announces Strategic Collaboration with AstraZeneca. ↗
Syneron Bio announced a strategic collaboration with AstraZeneca on macrocyclic peptide therapies for chronic diseases. The announcement does not establish clinical efficacy.
LIFE / A LITTLE ELSEWHERE
